Novartis Ag (NVS) Non-cash Items (2009 - 2010)
Novartis Ag recorded quarterly Non-cash Items of $315.0 in Q2 2010, down 11.02% quarter-over-quarter from $354.0 in Q1 2010, and up 5.35% year-over-year from $299.0 in Q2 2009.
Novartis Ag's Non-cash Items history runs 2 years deep, the most recent figure standing at $315.0 for Q2 2010.
- In Q2 2010, Non-cash Items rose 5.35% year-over-year to $315.0; the TTM figure through Jun 2010 stood at $315.0 (up 5.35% YoY), while the FY2025 annual figure was $11.2 billion, up 9.74% from the prior year.
- Non-cash Items came in at $315.0 for Q2 2010 at Novartis Ag, down from $354.0 in the prior quarter.
- In the past five years, Non-cash Items ranged from a high of $9927.0 in Q3 2009 to a low of $264.0 in Q1 2009.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2010 | 315.00 |
| Jun 30, 2010 | 315.00 |
| Mar 31, 2010 | 354.00 |
| Mar 31, 2010 | 354.00 |
| Dec 31, 2009 | 567.00 |
| Dec 31, 2009 | 567.00 |
| Sep 30, 2009 | 9,927.00 |
| Sep 30, 2009 | 9,927.00 |
| Jun 30, 2009 | 299.00 |
| Jun 30, 2009 | 299.00 |
| Mar 31, 2009 | 264.00 |
| Mar 31, 2009 | 264.00 |